Kuros Announces Allowance of European Patent for Synthetic Biomaterials

ZURICH, June 20, 2011 -

Kuros Biosurgery AG, a biotechnology company focused on the
development of novel biomaterials and bioactive-biomaterial
combination products for trauma, wound and spinal indications,
announced today the allowance of European Patent Application
00910049 by the European Patent Office. This now allowed patent
application is a key component of a broad portfolio of applications
and patents designed to protect Kuros’ synthetic biomaterial
(matrix) technologies and its product candidates which utilise this
technology. This novel synthetic matrix platform is a key source of
innovative products which will be important to Kuros’ future
successful development

Kuros is developing a portfolio of biomaterial, and
bioactive-biomaterial combination, products. The company’s product
candidates are based on two different matrix technology platforms;
synthetic or fibrin matrices. Kuros’ most advanced product
candidate based on its synthetic technology is Kuros’ dural sealant
product candidate (KUR-023) which is currently undergoing clinical
evaluation in Europe. Kuros intends that this clinical study will
enable CE marking in Europe.

Kuros’ most advanced products are based on a fibrin matrix and
include KUR-111 and KUR-113 which have achieved positive results in
Phase II trials for tibial plateau fractures and tibial shaft
fractures respectively.

Mr. href="www.kuros.ch/cms/front_content.php?idart=51">Didier
Cowling, Chief Executive Officer at Kuros
says: ”Obtaining the notice of allowance for this European
patent application further builds on Kuros’ proprietary position
around its key synthetic matrix technology platform.  This
platform is the basis of a number of Kuros’ novel product
candidates and strengthening the IP position around these
candidates adds significant value.”

The now allowed claims cover broadly Kuros` proprietary method
for forming biomaterials by nucleophilic addition mechanism
starting from functionalized precursor components, such as
functionalized PEGs. The claims cover the biomaterial (synthetic
matrix), its method of production, kits for delivery and several
uses. The allowance of the European application follows the grant
of the US applications as patents no. US 7,744,912 and US 7,413,739
which were granted with similar broad claims, as well as the grant
of the Canadian (CA 2,359,318), Mexican (MX 276585) and Australian
(AU 773 914) applications.

About Kuros

www.kuros.ch

Kuros is a biotechnology company that is focused on the
development of novel biomaterials and bioactive-biomaterial
combination products for trauma, wound and spinal indications.

Kuros has two biomaterial technology platforms, one based on
fibrin sealants and the other based on its own proprietary
synthetic technology that can mimic fibrin in many of its
attributes.  These materials can be used alone or in
combination with biologically active molecules.

The synthetic technology is tailorable and allows generation of
products that are delivered as liquids or gels but polymerise, in
or on living tissues, to form materials with different physical
properties.  For example, Kuros’ synthetic technology can be
utilized to develop products ranging from an elastic degradeable
dural sealant to a strong and non-degradeable bone cement.

Kuros’ combination products are designed to mimic the body’s
natural healing process. The products consist of fusion proteins of
naturally occurring bioactive factors, covalently incorporated into
fibrin or synthetic matrices. The incorporation of the biologically
active molecules into the injectable matrices aims to maximize
their activity by retention at the site of action. Kuros products
are designed to combine ease of application with localized
delivery. Kuros has a number of methodologies to achieve the
desired retention and release profiles of the biologically active
molecules.

Kuros’ has a diverse pipeline of product candidates with its
most advanced product candidates being in trauma and wound
care.

Since its creation, Kuros has raised over $100 million. The
company is located in Zurich, Switzerland.

Press Enquiries

Kuros
Didier Cowling, CEO            
           +41(0)44-200-56-62
Alistair Irvine, Director of
Business Development      
               
+41(0)44-200-56-62

For Swiss Media Enquires:
IRF Communications
Martin Meier-Pfister            
           +41(0)43-244-81-40
Jan Gregor                
       
       
 +41(0)43-244-81-54

For International Media Enquires:
Citigate Dewe Rogerson
David Dible, Nina Enegren            
       +44(0)207-638-9571

.